Toxic smallcaps are stocks that suddenly get new financing and skyrocket, only to fall over the timeframe afterwards. Good examples of what some forum posters say are toxic smallcaps are PLNI and QBID, though I'm sure there are a couple of rising stars.
MLXO I know for a fact was approached by Cornell capital in such a way. It's now basically one of those companies that has been used up, and I think the toxic financing is over, but MLXO will never recover again.
There's also a game to this. Post the stock ticker of a company here and if it goes from .0010 or lower to .01 or higher and then falls to .0010 or lower again over the course of 18 months.
There's no limit to how many entries you can have, and there's no keeping score, it's just interesting to see how many people can pick out the toxic financed penny stocks and who cannot.
Good luck!
Posted by HILANDER on :
I dunno, IGTN's R/S went through today. They are now IGTG after a 40:1 split.
Posted by glassman on :
there are so many....
these guys here: SPEX
Spherix Incorporated $4 Million Standby Equity Distribution Agreement
Common Stock between the Company and Cornell Capital Partners, L.P.
JUST sold 82,000 shares to Cornell Capital on Nov 30..... for $1.28
look what they did yesterday.....
Posted by glassman on :
and here she goes again Posted by glassman on :
XSUNX is also kicking some a$$$$$$...
Aliso Viejo, CA, July 18, 2005 – XsunX, Inc. (OTCBB: XSNX), developer of Power Glass™ -- an innovative solar technology that allows glass windows to produce electricity from the power of the sun, announced today that it has secured a total of $10,850,000 in financing with Cornell Capital Partners LP to support the continued development and growth of the Company.
Power Glass™..... hmmmm i like that
Posted by glassman on :
here's one that Cornell signed up recently and hasn't popped (YET)
i'm not in yet....
Titan Announces $35 Million Equity Agreement
SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (Amex:), announced today that it has entered into an equity line of credit agreement with Cornell Capital Partners, LP. Under the agreement, Cornell has agreed to provide up to $35 million of funding that can be accessed at the Company's discretion over a 24-month period through issuance of common stock of the Company. Any sale of common shares to Cornell will be based on a five day weighted average market price at the time of the transaction, and Cornell will receive a five percent fee on the value of such stock purchase. Proceeds received by the Company will be used for product development activities, as well as for general corporate purposes.
![[Big Grin]](biggrin.gif)